Sequential Gastroenteritis Outbreaks in a Single Year Caused by Norovirus Genotypes GII.2 and GII.6 in an Institutional Setting

Consolee K. Karangwa, Gabriel I. Parra, Karin Bok, Jordan A. Johnson, Eric A. Levenson, and Kim Y. Green

Caliciviruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, DHHS, Bethesda, Maryland

Background. Norovirus is a leading cause of acute gastroenteritis worldwide. Improved diagnostic capability has been instrumental in the characterization of archival norovirus strains associated with gastroenteritis outbreaks that were investigated decades ago. One such investigation was that of 2 sequential gastroenteritis outbreaks that occurred in 1971 at the former Henryton State Hospital in Maryland. Approximately 40% of the resident population experienced clinical symptoms in both outbreaks, which occurred 11 months apart.

Methods. Stored stools and paired sera were re-analyzed to investigate the etiology of the 2 outbreaks.

Results. Different norovirus genotypes were identified as the etiological agents responsible for the illnesses, with GII.2 associated with the first outbreak and GII.6 with the second. The viruses were antigenically distinct as determined by analyses of hyperimmune sera raised against the corresponding virus-like particles in animals, as well as paired sera from infected individuals.

Conclusions. The observed antigenic differences were consistent with the failure of the GII.2 strain to provide cross-protective immunity to the GII.6 strain a few months later. An understanding of antigenic diversity among norovirus genotypes will be important in the design of norovirus vaccines.

Keywords. calicivirus; gastroenteritis; norovirus; outbreak; reinfection.

Norovirus is a leading cause of acute nonbacterial gastroenteritis [1, 2]. The positive-sense norovirus RNA genome is organized into 3 open reading frames (ORFs). ORF1 encodes the viral RNA-dependent RNA polymerase (RdRp) and other nonstructural proteins, ORF2 the major capsid protein (VP1), and ORF3 the minor capsid protein (VP2) [3]. The VP1 is comprised of 2 major domains: the inner shell (S) and the protruding (P) arm, which is further divided into the P1 and P2 subdomains [4]. The hypervariable, surface-exposed P2 subdomain contains major antigenic and histo-blood group antigen (HBGA) binding sites, both playing an integral role in determining susceptibility to infection [5–7]. Upon expression, the VP1 can self-assemble into virus-like particles (VLPs) that are antigenically similar to the native virion [8].

Noroviruses cluster into 7 genogroups (GI-GVII), with GI and GII responsible for most human illnesses [9]. There are presently 9 distinct genotypes within GI and 22 within GII, with GII.4 as the predominant virus causing epidemics worldwide [9, 10]. Early human volunteer challenge studies suggested that homologous immunity to Norwalk virus (a prototype GI virus) is only short term, with a period of 6 months to 2 years, and that heterologous protective immunity to Hawaii virus (a prototype GII virus) was not induced [11, 12]. A recent mathematical modeling of incidence data suggested that homologous immunity may endure 4 years or longer [13], and a growing number of reports have documented sequential norovirus infections with different genotypes in the same individual [14–16].

Sensitive diagnostic techniques have been instrumental in the characterization of norovirus specimens collected more than 4 decades ago [17]. Two sequential gastroenteritis outbreaks occurred during 1971 at the Henryton State Hospital (now closed) in Marriottsville, Maryland [18], that were characterized by self-limiting nonbacterial acute gastroenteritis of unknown etiology that affected the residential population in January (90 residents) and December (64 residents). Approximately 40% of residents who presented with acute gastroenteritis in the January outbreak experienced disease symptoms again in the December outbreak, suggesting that the first infection did not confer short-term (greater than 1 year) protective immunity to the second infection [18]. The purpose of this study was to identify the presumptive viral pathogens responsible for these sequential outbreaks in an institutional setting to gain insight into the apparent absence of immunity in the second outbreak.
METHODS

Specimens

Samples were collected during regional gastroenteritis outbreak investigations by the National Institutes of Health (NIH) [18], which took place soon after the discovery of the Norwalk virus [19]. Briefly, stool specimens (collected as rectal swabs) with corresponding acute and convalescent serum samples were available for the present study from 1 out of 90 and 55 out of 64 ill individuals residing at the Henryton State Hospital in January and December of 1971, respectively, when the 2 acute nonbacterial gastroenteritis outbreaks occurred (Table 1). A volunteer challenge study designed to investigate the etiology of the first outbreak in January 1971 provided an additional stool specimen from an ill volunteer (17LI), along with serum samples collected 4 days prechallenge and at day 1 (D1), D7, D14, D21, D28, and D57 postchallenge [18]. The ill volunteer was rechallenged 2 months later with the homologous agent and did not develop clinical symptoms of gastroenteritis following rechallenge. A serum sample was collected approximately 2 months following the second challenge (D135). The rectal swab specimens and acute phase sera from the second outbreak in December 1971 were collected 48 hours after the peak incidence of illness, which corresponded to the 10th day after the first case was reported. Based on the available recorded data, 44 of the 55 (80%) stool samples were collected within the first 5 days of infection. Convalescent phase serum day 57 was collected 6 weeks later on January 26, 1972 [18]. Records were not available from individual residents in the chronic care Henryton State Hospital that would inform an underlying condition or that would allow a direct comparison of the clinical features between a first and second gastrointestinal illness in the 2 outbreaks. The low turnover of the patient population and the re-infection rate (approximately 40%) used in this study were those reported from the original outbreak investigation [18].

All samples have been stored in the NIH Laboratory of Infectious Diseases. An exemption for the analysis of archival specimens in the repository was obtained from the NIH Office of Human Subjects Research and Protection.

Viral RNA Extraction and Genotyping

Viral RNA was extracted from stool in rectal swab samples with the MagMAX Viral RNA Isolation Kit (Life Technologies Corp., Carlsbad, CA) and amplified in a reverse-transcription polymerase chain reaction (RT-PCR) using universal primers (290 and 289) that target the norovirus RdRp region [20]. The amplicons were sequenced using a Big Dye terminator cycle sequencing ready reaction kit (Applied Biosystems), and the norovirus typing tool was used to assign genotype [10, 21]. The near full-length genome sequences were determined as described previously [22]. In addition, the authentic 5’- and 3’-end genomic sequences were verified using the Roche 5’/3’ RACE Kit, 2nd Generation (Roche Diagnostics Corporation, Indianapolis, IN) according to the manufacturer’s protocol.

Phylogenetic Analyses

Phylogenetic analyses of ORF2 were performed as previously described using the neighbor-joining and Tajima-Nei methods [22] in the Molecular Evolutionary Genetics Analysis program, version 7 [23].

Structural Modeling

The capsid monomer from each Henryton virus (GII.2 and GII.6) was modeled upon a known GII.4 VP1 structure (3SEJ) with I-TASSER [24]. The electrostatic potential of amino acid residues on the surface of the resulting protruding domain model was calculated with UCSF Chimera [25].

Expression and Purification of VLPs

To express VLPs, the consensus ORF2 gene of the norovirus strain GII/Hu/US/1971/GII.2/HenrytonSP17 was amplified and cloned into the pENTR Gateway vector (Invitrogen, Grand Island, NY). Recombination with baculovirus DNA was performed using the Baculodirect kit, as recommended by the manufacturer (Invitrogen). The consensus ORF2 gene of the norovirus strain GII/Hu/US/1971/GII.6/HenrytonSP24 was synthesized with flanking Sall and Not1 restriction enzyme sites (New England Biolabs) and cloned into the corresponding sites of the pFastBac vector. Recombination with baculovirus DNA was performed using the Bac-to-Bac system (Invitrogen).

Table 1. Features of 2 Acute Infectious Nonbacterial Gastroenteritis Outbreaks at the Henryton State Hospital, Maryland, in 1971 and Samples Available for this Study

| Month of Outbreak | III Individuals/Total Residents (%) | Stools Available/III Individuals (%) | Number Stools Positive for Norovirus by RT-PCR (%) | Norovirus Capsid Genotype | Number Paired Sera Available (Day Collected)a |
|-------------------|------------------------------------|------------------------------------|-----------------------------------------------|---------------------------|---------------------------------------------|
| January           | 90/367 (25)                        | 1/90 (1)                           | 1/1                                           | GII.2 (1/1)               | 1 (d13 & d109)                             |
| December          | 64/382 (17)                        | 55/64 (86)                         | 38/55 (69)                                    | GII.6 (38/38)             | 55 (d10 & d57)                             |

Abbreviation: RT-PCR, reverse-transcription polymerase chain reaction.

aAcute or convalescent serum collection day (d) corresponds to the number of days after the first case was reported for each outbreak.

bThe stool from this resident was administered to an adult volunteer who developed illness following oral challenge (18). Our present study reports that the ill volunteer shed GII.2 norovirus and developed a serologic response to the challenge strain.

cTwenty-six (41%) of these 64 individuals presenting gastroenteritis symptoms also reported illness in the January outbreak (18).
A baculovirus stock for each strain was generated, and the purification and expression of VLPs representing the GII.2 and GII.6 viruses were carried out as previously described [15]. The protein concentration of each VLP was determined with a commercial Bradford assay kit (Pierce, Rockford, IL).

**Generation of Hyperimmune Sera in Guinea Pigs**

Hyperimmune sera specific to the Henryton GII.2 and GII.6 VLPs were produced in guinea pigs under an approved National Institute of Allergy and Infectious Diseases Institutional Animal Care and Use Committee animal study protocol [7]. Animal work was conducted according to the institution’s guidelines for animal use and followed the guidelines and basic principles in the United States Public Health Service Policy on the Humane Care and Use of Laboratory Animals and the Guide for the Care and Use of Laboratory Animals by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care International–accredited facility on the NIH campus in Bethesda, Maryland.

**Enzyme-Linked Immunosorbent Assay**

Norovirus GII.2 and GII.6 Henryton VLPs were used as antigens in an enzyme-linked immunosorbent assay (ELISA) to measure antibody titers, as described previously [15]. Sera were subjected to serial dilution, and binding of antibodies to the VLPs was detected with either antihuman immunoglobulin G (IgG) conjugated with horseradish peroxidase or guinea pig anti–guinea pig IgG conjugated with horseradish peroxidase. ELISA titers were calculated using the reciprocal of the highest serum dilution that yielded a positive signal, defined as an optical density absorbance value at 405 nm (OD405) of ≥0.2.

**Hemagglutination Inhibition Assay**

Hemagglutination inhibition (HAI) assays for the detection of norovirus-specific antibodies were performed as described [26] with B+ red blood cells (RBCs) from a healthy adult donor. HAI titers were calculated as the reciprocal of the highest dilution of serum that inhibited hemagglutination of RBCs by the target norovirus VLP.

**Fucosyl Transferase Gene 2 Genotyping**

DNA was extracted from serum (200 µL) using the DNaseasy Blood & Tissue Kit (Qiagen) and amplified in an RT-PCR reaction using a primer pair that proved to be optimal in the reaction: forward 5'-GATGGAGGAGGAATACCCGCAC-3' [27] and reverse 5'-GGCTGCCTCTGGCTTAAAG-3' [28], which target position 428 of the FUT2 gene. Human growth hormone–specific gene primers were used as an internal PCR control to produce a 428-bp amplicon [28, 29]. Amplicons were sequenced, and the FUT2 genotype was assigned by analysis of the sequencing chromatogram for each individual; a single G peak at position 428 of the FUT2 gene signified a homozygous secretor, a mixed population of 2 peaks (G and A) signified a heterozygous secretor, and a single A peak signified a homozygous nonsecretor.

**RESULTS**

**Association of Noroviruses With the Henryton Hospital Outbreaks**

To establish the etiology of the 2 sequential outbreaks of gastroenteritis that occurred at the Henryton Hospital in January and December of 1971, the 56 available stool specimens obtained from residents experiencing gastroenteritis were analyzed for the presence of norovirus by a diagnostic RT-PCR that targets the RdRp (Table 1). Norovirus was detected in 39/56 (70%) of the stool specimens from ill residents, and amplicon sequences matched 2 distinct genotypes; a GII.2 norovirus was associated with the January outbreak (88% nucleotide identity match with GII/Hu/US/1975/GII.2/SnowMountain), and a GII.6 norovirus was associated with the December outbreak (92.1% nucleotide identity match with GII/Hu/JP/2009/GII.6/OH09014). An adult volunteer received an oral challenge with a stool filtrate derived from a resident in the January outbreak and developed gastroenteritis [18]. The GII.2 norovirus detected in the volunteer’s stool was nearly identical to that of the resident.

**Sequence Analyses and Phylogenetic Relationships**

The full-length genome sequence was determined for each outbreak virus. The January GII.2 and December GII.6 norovirus genomes were 7536 and 7553 nucleotides in length, respectively, with an overall identity of 64.9%. Phylogenetic comparisons of the norovirus capsid regions (encoded in ORF2) with reference GI and GII sequences showed that each Henryton norovirus clustered closely with a specific genotype, GII.2 (highlighted in rust), or GII.6 (highlighted in blue) (Figure 1A). The GII.6 viruses form 3 genetic clusters, designated here as A, B, and C. The Henryton GII.6 norovirus grouped within cluster C, which includes viruses detected in the United States and Japan during 2008–2012 [22, 30]. The Henryton GII.2 norovirus grouped with the single cluster of the GII.2 genotype represented by the prototype Snow Mountain virus, which has remained highly conserved for approximately 40 years [22]. Alignment of the VP1 amino acid sequences revealed that the GII.2 and GII.6 Henryton viruses differed by 28.3% (157/554), with the capsid P domain having the greatest amino acid variation (36.6%; 120/328) and the S domain having the least (16.4%; 37/226). The Henryton outbreak viruses were designated as GII/Hu/US/1971/GII.2/HenrytonSP17 and GII/Hu/US/1971/GII.6/HenrytonSP24 and assigned the GenBank accession numbers MF405169 and KY424345, respectively.

**Antigenic Comparison of the Henryton Noroviruses**

Electrostatic modeling of each Henryton norovirus capsid monomer showed an overall similarity in the surface charge distribution, but with a notable difference in the exposed surface of the P2 subdomain (Figure 1B). To explore antigenic differences, VLPs representing the Henryton GII.2 and GII.6 outbreak viruses were generated and VLP-specific hyperimmune serum was raised in guinea pigs. The antigenic relationship between the 2 capsids was examined by ELISA (Figure 1C).
and HAI (Figure 1D) assays. In both assays, the homologous titer against the immunizing VLP was higher (≥5-log) than that against the heterologous VLP, consistent with antigenic differences between the 2 viruses.

**FUT2 Secretor Status Genotyping**

An association between the FUT2 gene allele sequence at 428 and susceptibility to norovirus infection was investigated (Table 2). Of the 55 residents with serum samples available for genotyping analysis in the December GII.6 outbreak, the majority (73%) were identified as secretors. Evidence for norovirus infection, as determined by the identification of GII.6 norovirus RNA in stool, was found in 38 (69%) of these 55 individuals. Of these 38, 30 (79%) were identified as secretors and 8 (21%) as nonsecretors. The adult volunteer who developed illness following challenge with the GII.2 norovirus from the January outbreak was genotyped as a nonsecretor (data not shown).

**Seroological Response of an Adult Volunteer Challenged With the GII.2 Outbreak Virus**

The GII.2 and GII.6 Henryton VLPs were utilized as antigens in an ELISA to detect the virus-specific serum antibody response
of the adult volunteer (17LI) challenged with the Henryton GII.2 virus. The homologous GII.2-specific and heterologous GII.6-specific serum IgG titers were 12,800 (Figure 2A) at the time of the initial challenge, when the volunteer developed illness. After the initial challenge, GII.2-specific serum IgG titers peaked to a titer of 819,200 (the heterologous response to GII.6 was lower) and steadily decreased over time but did not return to prechallenge levels (Figure 2A). The homologous serum IgG titer 5 days prior to rechallenge with the GII.2 outbreak virus (that occurred at day 62 after the first challenge) was 204,800, 16-fold higher than the titer at the time of the first challenge. The volunteer did not develop illness, consistent with the development of short-term homologous immunity after the first challenge.

Certain norovirus VLPs display hemagglutination activity with human RBCs, and an increase in antibodies that inhibit this activity (HAI) can be detected in individuals following norovirus infection or human experimental challenge [26]. Moreover, HAI has been used as a surrogate neutralization assay [26]. We examined the HAI titers of volunteer 17LI at the time of initial challenge with the Henryton GII.2 virus. The homologous serum HAI titer at the time of the first challenge, when the volunteer developed illness, was 2560, consistent serum collected 109 days later. Although an anamnestic response resulting from previous exposure to norovirus was likely already in progress, the resident showed a 4-fold antibody response against the homologous GII.2 outbreak virus by both ELISA (titer change from 12,800 to 51,200) and HAI (titer change from 160 to 640). Of note, there was no change in the HAI titer of 40 against GII.6 VLPs.

Fifty-five paired acute and convalescent sera were available from ill residents in the December 1971 GII.6 norovirus outbreak (Table 1), and we tested them against both VLP antigens by ELISA and HAI. It should be noted that the acute sera in the second outbreak were collected only once at day 10 following the first report of illness, potentially allowing time for the initiation of an anamnestic or primary adaptive response in some individuals. First, we measured the antibodies by ELISA (Figure 2). Analysis of the acute phase sera showed that there were no seronegative individuals and that the majority of the residents 48/55 (87%) possessed IgG antibody titers between 1600 and 12,800 against both Henryton antigens at the time of the December outbreak (Figure 2C). The IgG titer distribution in convalescent phase serum showed a shift to higher titers, as 35/55 (64%) of the residents developed a serologic response to the homologous GII.6 virus (Figure 2D), with end-point titers ranging between 6400 and 51,200 for the majority of individuals (Figure 2C). A serologic response in 17/55 (31%) of the residents was observed against the heterologous GII.2 virus as well. As noted above, a homologous GII.2 serum ELISA titer of 12,800 did not correlate with protection in volunteer 17LI at the time of initial challenge with the GII.2 Henryton norovirus. Likewise, 33/48 (69%) residents exhibited a homologous GII.6 serum titer of up to 12,800 at the time of the GII.6 outbreak, suggesting that this ELISA titer may not reflect immunity to GII.6. A serological response (≥4-fold increase) was detected in 35/55 (64%) residents against homologous GII.6 VLPs, in contrast to 15/55 (27%) against heterologous GII.2 VLPs (Figure 2B). Of the residents exhibiting a heterologous GII.2 serological response, 11/15 (73%) were positive for GII.6 virus shedding in the second outbreak. However, it was noteworthy that 2-fold increases did occur in more than half of the residents against the GII.2 virus, possibly reflecting an anamnestic response related to infection during the first outbreak. Considering both 4-fold and 2-fold increases combined, 49/55 (89%) developed a serologic response to the homologous GII.6 outbreak virus, as determined by ELISA.

The 55-paired sera collected during the GII.6-associated December outbreak were tested next against both VLPs in an HAI assay (Figure 3). The distribution of homologous GII.6 HAI titers in the acute phase sera showed that approximately 25/55 (45%) had titers ≤40 (Figure 3C). Of these, 18/25 (72%) shed GII.6 norovirus in stool. Of the remaining 30 residents with homologous acute phase HAI titers >40, 20 (67%) were infected with GII.6 norovirus, as determined by detection of the virus in stool. Interestingly, the distribution of HAI titers against the heterologous GII.2 was higher, with 49/55 (89%) residents having titers ≥80 in their acute phase sera, likely reflecting infection with the first outbreak virus (Figure 3C). The majority of residents (53/55) displayed HAI end-point titers ≥80 in their convalescent phase

### Table 2. FUT2 Secretor Genotype in Henryton State Hospital Residents and Norovirus Infection

| FUT2-Genotypeda | Residents (%) (n = 55) | No. Norovirus Positiveb (%) (n = 38) | No. Norovirus Negative (%) (n = 17) |
|------------------|------------------------|-------------------------------------|-----------------------------------|
| Secretors        |                        |                                     |                                   |
| SeSe             | 12 (22)                | 7 (18)                              | 5 (29)                            |
| Sese428          | 28 (51)                | 23 (61)                             | 5 (29)                            |
| Subtotal         | 40 (73)                | 30 (79)                             | 10 (59)                           |
| Nonsecretors     |                        |                                     |                                   |
| se428se428       | 15 (27)                | 8 (21)                              | 7 (41)                            |

aG428A mutation site in FUT2 gene.
bPositive is defined as the detection of norovirus RNA in stool.
serum against both VLPs (Figure 3D). In 43/55 (78%) residents, a ≥4-fold increase in GII.6 antibody titer was detected between acute and convalescent phase serum, indicative of a GII.6 infection (Figure 3B). Norovirus (GII.6) was detected in the stools of 77% (33/43) of these residents. A cross-reactive GII.2 serological response was detected in 25% (14/55) of the residents exposed to the GII.6 virus. Of the 14 residents who responded serologically to both GII.6 and GII.2 VLPs as determined by the HAI assay, 12 (86%) were positive for GII.6 norovirus shedding.

DISCUSSION

Norovirus-associated gastroenteritis outbreaks are a major concern in closed institutional settings, where the potential for person-to-person transmission is high [1, 18]. Herd immunity would provide an important source of protection against recurrent norovirus episodes in this setting [31, 32]. We analyzed specimens from 2 sequential outbreaks that occurred 11 months apart in the same institution; a GII.2 norovirus caused a January outbreak, followed by a GII.6 outbreak in December. Although the 2 outbreak viruses both belonged to Genogroup II and shared a common ancestral lineage, our data indicate that the viruses have evolved as antigenically distinct genotypes. This observation is consistent with the lack of observed cross-protection in the residential hospital population between the GII.2 and GII.6 outbreak viruses and our analysis of virus-specific antibody responses in immunized animals and infected individuals.

A comparison of hyperimmune sera raised against VLPs from the GII.2 and GII.6 Henryton noroviruses provided
direct evidence that the viruses were antigenically distinct. Cross-reactive antibodies were also detected, albeit at lower levels. The relatively higher levels of preexisting GII.2-specific HAI antibodies in the Henryton population at the time of the second GII.6 outbreak (the majority with GII.2 HAI titers $\geq 80$) and the absence of cross-protection further supported the antigenic diversity of these viruses. However, serological correlates of immunity and the role of serotypes remain difficult to define [12, 33, 34], and our clinical records in this study were incomplete. Surrogate neutralization assays, such as HAI, have been used to establish potential correlates, such as proposed protective HAI titer of 40 for GI.1 Norwalk virus [26]. The adult volunteer (17LI) who underwent challenge with the GII.2 Henryton virus was not protected with a preexisting homologous HAI titer of 40, suggesting that serological correlates of resistance to illness may vary, depending on norovirus genotype and the assays employed [35].

Our data are consistent with recent reports that reinfection with noroviruses from different genotypes occurs often in children [16, 22, 36] and that norovirus reinfections can occur within a single year in both children and adults [14, 15]. Similar to our previous report that infection with 2 different GII genotypes (GII.4 followed by GII.6) could occur within a single year in a young child [15], we show here that yet another GII genotype pairing (GII.2 followed by GII.6) could cause sequential outbreaks in adults within a single year. In addition to the antigenic differences that were observed between the 2 Henryton outbreak viruses, we explored the role of the FUT2 gene, first associated with host resistance to the GI.1 prototype Norwalk virus [34, 37, 38]. This genetic marker may not be applicable to all norovirus genotypes [27, 39]. One of 9 ill volunteers challenged with the GII.2 Snow Mountain norovirus was identified as secretor negative [40], and the ill volunteer challenged with the Snow
Mountain–like Henryton GII.2 norovirus in this study was also secretor negative. Approximately 21% of the Henryton residents who shed GII.6 norovirus in stool and who developed antibodies against GII.6 were secretor negative, indicating that a functional fucosyl transferase enzyme (as determined by the FUT2 genotype at position 428) was not essential to confer susceptibility to this GII.6 norovirus. The role of HBGA carbohydrates in the binding of these noroviruses to host cells in both secretor and nonsecretor individuals will require additional investigation.

In summary, our study characterized the etiological agents, both of which are the oldest viruses known to date within their respective genotypes, responsible for sequential illnesses at a state hospital in 1971. The immunological responses of residents exposed to the 2 different norovirus genotypes suggest the absence of cross-reactive immunity, independent of preexisting norovirus antibodies from previous exposure history. The most likely interpretation of our data is that GII.2 and GII.6 viruses are antigenically distinct and likely represent distinct serotypes. Moreover, GII.2 and GII.6 belong to different “immunotypes,” our recently proposed system that defines clusters of antigenically related genotypes [22]. Continued analyses of antigenic diversity will be important in the development of broadly protective norovirus vaccines.

Acknowledgments

Financial support. This research was funded by the Division of Intramural Research of National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Potential conflicts of interest. All authors: no reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198–205.
2. Kaufman SS, Green KY, Korba BE. Treatment of norovirus infections: moving antivirals from the bench to the bedside. Antiviral Res 2014; 105:80–91.
3. Thorne LG, Goodfellow IG. Norovirus gene expression and replication. J Gen Virol 2014; 95:278–91.
4. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999; 286:287–90.
5. Tan M, Huang P, Meller J, Zhong W, Farkas T, Jiang X. Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J Virol 2003; 77:12562–71.
6. Debink K, Donaldson EF, Lindemuth LC, Baric RS. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol 2012; 86:1214–26.
7. Parra GI, Abente EI, Sandoval-Jaime C, Sosnovtsev SV, Bok K, Green KY. Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. J Virol 2012; 86:7414–26.
8. Jiang X, Wang M, Graham DT, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66:5627–32.
9. Vinje J. Advances in laboratory methods for detection and typing of norovirus. J Clin Microbiol 2015; 53:373–81.
10. Kroneman A, Vega E, Vennema H, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013; 158:2059–68.
11. Wyatt RG, Dolin R, Blackow NR, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 1974; 129:709–14.
12. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blackow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 1977; 297:86–9.
13. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 2013; 19:1260–7.
14. Ayukokong JA, Fobisong C, Tah E, Lindh M, Nkou-Akenji T, Bergstrom T. Pattern of circulation of norovirus GII strains during natural infection. J Clin Microbiol 2014; 52:4253–9.
15. Parra GI, Green KY. Sequential gastroenteritis episodes caused by 2 norovirus genotypes. Emerg Infect Dis 2014; 20:10168–7.
16. Saito M, Goel-Apasa S, Espetia S, et al. Norovirus Working Group in Peru. Multiple norovirus infections in a birth cohort in a Peruvian Perurban community. Clin Infect Dis 2014; 58:483–91.
17. Rackoff LA, Bok K, Green KY, Kapikian AZ. Epidemiology and evolution of rotaviruses and noroviruses from an archival WHO Global Study in Children (1976–79) with implications for vaccine design. PLoS One 2013; 8:e59394.
18. Buscho R, Wyatt BG, Dolin R, Blackow NR, DuPont HL, Channock RM. Recurrent institutional outbreaks of acute infectious nonbacterial gastroenteritis: epidemiology and etiology. Am J Epidemiol 1973; 98:192–8.
19. Kapikian AZ, Wyatt RG, Dolin R, Thornhill TS, Kalica AR, Channock RM. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol 1972; 10:1075–81.
20. Jiang X, Huang PW, Zhong WM, Farkas T, Cubit DW, Matson DO. Design and evaluation of a primer pair that detects both Norwalk- and Sapporo-like caliciviruses by RT-PCR. J Virol Methods 1999; 83:145–54.
21. Kroneman A, Vennema H, Deforche K, et al. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol 2011; 51:121–5.
22. Parra GI, Squires RB, Karangwa CK, et al. Static and evolving norovirus genotypes: implications for epidemiology and immunity. PLoS Pathog 2017; 13:e1006136.
23. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol 2016; 33:1870–4.
24. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 2010; 5:725–38.
25. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605–12.
26. Zakó R, Atmar RL, Opekun AR, Gälger MA, Graham DT, Estes MK. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol 2012; 19:284–7.
27. Carlsson B, Kindberg E, Buesa J, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic G44 Norovirus infection. PLoS One 2009; 4:e5593.
28. Thovren M, Grahn A, Hedlund KO, et al. A homozygous nonsense mutation (426G->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol 2005; 79:13531–5.
29. Procter J, Crawford J, Bunce M, Welsh KI. A rapid molecular method (polymerase chain reaction with sequence-specific primers) to genotype for ABO blood group and secretor status and its potential for organ transplants. Tissue Antigens 1997; 50:475–83.
30. Chan-H W, Thongprachum A, Khamrin P, et al. Emergence of a new norovirus GII.6 variant in Japan, 2008–2009. J Med Virol 2012; 84:1089–96.
31. Cannon JL, Lindemuth LC, Donaldson EF, Saxe L, Baric RS, Vinje J. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol 2009; 83:5363–74.
32. Lindemuth LC, Donaldson EF, Lobue AD, et al. Mechanisms of G44 norovirus persistence in human populations. PLoS Med 2008; 5:e33.
33. Johnson PC, Mathewson J, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 1990; 161:18–21.
34. Lindemuth L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548–53.
35. Atmar RL, Bernstein DI, Lyon GM, et al. Serological correlates of protection against a G44 norovirus. Clin Vaccine Immunol 2015; 22:922–93.
36. Sakon N, Yamazaki K, Nakata K, et al. Impact of genotype-specific herd immunity on the circulatory dynamics of norovirus: a 10-year longitudinal study of viral acute gastroenteritis. J Infect Dis 2015; 211:879–88.
37. Hutson AM, Airaudi L, PeLePudo J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol 2005; 77:116–20.
38. Marionneau S, Ruvoën N, Le Mouillac-Vaidye B, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 2002; 122:1967–77.
39. Nordgren G, Kindberg E, Lindgren PF, Matsusek A, Svensson L. Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. J Med Virol 2002; 71:223–7.